Base-case cost-effectiveness analysis
| Baseline model . | PSA model . | |||||
|---|---|---|---|---|---|---|
| Strategy . | Costs (US$) . | Incremental costs (US$) . | Effectiveness (QALY) . | Incremental effectiveness (QALY) . | ICER ($ per QALY) . | ICER 95% CI ($ per QALY) . |
| Ibrutinib first-line | $1 367 275 | $612 700 | 6.85 | 0.26 | $2 350 041 | $939 719-dominated |
| Delayed ibrutinib | $754 575 | — | 6.59 | — | — | — |
| Baseline model . | PSA model . | |||||
|---|---|---|---|---|---|---|
| Strategy . | Costs (US$) . | Incremental costs (US$) . | Effectiveness (QALY) . | Incremental effectiveness (QALY) . | ICER ($ per QALY) . | ICER 95% CI ($ per QALY) . |
| Ibrutinib first-line | $1 367 275 | $612 700 | 6.85 | 0.26 | $2 350 041 | $939 719-dominated |
| Delayed ibrutinib | $754 575 | — | 6.59 | — | — | — |
—, not applicable.